Диссертация (Комплексная характеристика артериального русла и суточного профиля центрального артериального давления у пациентов с артериальной гипертонией и сахарным диабетом второго типа), страница 22

DiabetesCare 2003; 26: 2133–2138.222.Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA,Vasan RS, and Levy D: Changes in arterial stiffness and wave reflection withadvancing age in healthy men and women: the Framingham Heart Study.Hypertension 2004; 43: 1239–1245.223.Vyas M, Izzo JL Jr, Lacourciere Y, Arnold JM, Dunlap ME, Amato JL,Pfeffer MA, Mitchell GF: Augmentation index and central aortic stiffness inmiddle-aged to elderly individuals. Am J Hypertens 2007; 20: 642–647224.Mitchell GF: Effects of central arterial aging on the structure andfunction of the peripheral vasculature: implications for end-organ damage. JAppl Physiol (1985) 2008; 105: 1652–1660225.Hashimoto J, Ito S: Central pulse pressure and aortic stiffness determinerenal hemodynamics: pathophysiological implication for microalbuminuria inhypertension. Hypertension 2011; 58: 839–846.226.Tarumi T, Shah F, Tanaka H, Haley AP: Association between centralelastic artery stiffness and cerebral perfusion in deep subcortical gray andwhite matter.

Am J Hypertens 2011; 24: 1108–1113227.Catherine Fortier, Fabrice Mac-Way, Simon Desmeules end al. Aortic-BrachialStiffnessMismatchandMortalityinDialysisPopulationHypertension. published online December 1, 2014; HYPE201404587D-R1228.Национальные рекомендации по диагностике и коррекциинарушений липидного обмена с целью профилактики и леченияатеросклероза, четвертый пересмотр//Российский кардиологическийжурнал. – 2012.

- №4. - Приложение 1229.http://boris.bikbov.ru/2013/07/21/kalkulyator-skf-rascheta-skorostiklubochkovoy-filtratsii/230.Горбунов В.М. Некоторые вопросы практического использованиясуточного мониторирования артериального давления// Клиницист. – 2008.– № 3. – С. 30–39. Рогоза А.Н., Ощепкова Е.В., Цагареищвили Е.В.,Гориева Ш.Б. Современные неинвазивные методы измеренияартериального давления для диагностики артериальной гипертонии и135оценки эффективности антигипертензивной терапии//М.: Медика, 2007. –76с231.Cheng H., Chuang S., Sung S.

et al. Derivation and Validation ofDiagnostic Thresholds for Central Blood Pressure Measurements Based onLong-Term Cardiovascular Risks. J Am Coll Cardiol 2013;62(19):1780-7.232.Herbert A., Cruickshank J., Laurent S., Boutouyrie P. Establishingreference values for central blood pressure and its amplification in a generalhealthy population and according to cardiovascular risk factors. Eur Heart J2014;35(44):3122-33233.Руководство по эксплуатации к прибору VaSera VS – 1000 CAVIplus.

Fukuda Denshi. – С. 139234.Nakamura K., Tomaru T., Yamamura S., et al. Cardio -ankle vascularindex is a candidate predictor of coronary atherosclerosis Circulation2008;72:598-604. doi: 10.1161/HYPERTENSIONAHA.112.194779235.Gomez-Marcos M.A., J.I. Recio-Rodriguez , Patino-Alonso M.C et al.Cardio-ankle vascular index is associated with cardiovascular target organdamage and vascular structure and function in patients with diabetes ormetabolic syndrome, LOD-DIABETES study: a case series report. CardiovascDiabetol 2015;14:7. doi: 10.1186/s12933-014-0167-y236.Ryde´n L, Grant P, Anker SD, Berne C, Cosentino F, Danchin N, et al.ESC Guidelines on diabetes, prediabetes, and cardiovascular diseasesdeveloped in collaboration with the EASD: the Task Force on diabetes,prediabetes, and cardiovascular diseases of the European Society of Cardiology(ESC) and developed in collaboration with the European Association for theStudy of Diabetes (EASD).

Eur Heart J 2013; 34:3035–3087.237.Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC guidelinesfor the management of arterial hypertension: the Task Force for theManagement of Arterial Hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). EurHeart J. 2013;34(28):2159–219.238.Russian society of arterial hypertension/Russian society of cardiology.Diagnosis and treatment of arterial hypertension. Russian guidelines// SistemicHypertension., 2010;3:5-26 – Russian.

(Российское медицинское общество136по артериальной гипертонии (РМОАГ), Всероссийское научное обществокардиологов (ВНОК). Диагностика и лечение артериальной гипертензии.Российскиерекомендации(четвертыйпересмотр).Системныегипертензии 2010;3:5—26.)239.ADVANCE trial study group rationale and design of the study:ADVANCE randomized trial of blood pressure lowering and intensive glucosecontrol in high-risk individuals with type 2 diabetes mellitus. J Hypertens2001;19: S21-S28.240.Сummings D.M., Doherty L., Howards G. et al. Blood pressure controlin diabetes: temporal progress yet persistent racial disparities: national resultsfrom the REasons for Geographic And Racial Differences in Stroke(REGARDS) study.

Diabetes Care. 2010 Apr;33(4):798-803.241.Izzo R., de Simone G., Chinali M. et al. Insufficient control of bloodpressure and incident diabetes. Diabetes Care. 2009 May;32(5):845-50242.Choma N., Griffin M., Kaltenbach L. et al. Blood pressure controlamong patients with hypertension and newly diagnosed diabetes. Diabet Med.2012;29(9):1126-33.243.Bonner G., Bakris G.L., Sica D., Weber M.A., White W.B., Perez A.,Cao C., Handley A., Kupfer S. Antihypertensive efficacy of the angiotensinreceptor blocker azilsartan medoxomil compared with the angiotensinconverting enzyme inhibitor ramipril.

J Hum Hypertens 2013;27:479–486244.Kurtz T.W., Kajiya T. Differential pharmacology and benefit/risk ofazilsartan compared to other sartans. Vasc Health Risk Manag 2012;8:133—143245.Kobalava Z.D., Villevalde S.V. Azilsartan medoxomil: new horizons inthe treatment of arterial hypertension. Pharmacological properties. Kardiologiia2014;12:57-62 – Russian (Кобалава Ж.Д., Виллевальде С.В.

Азилсартанамедоксомил: новые возможности в лечении артериальной гипертонии.Фармакологические свойства. Кардиология 2014;12:57-62)137246.Nedogoda S.V. Azilsartan: Whether it Will Expand Treatment Optionsfor Arterial Hypertension? Kardiologiia. 2015;55(4):97-100 – Russian(Недогода С.В. Азилсартан: расширит ли он возможности леченияартериальной гипертензии? Кардиология 2015;55(4):97-100).247.Национальныерекомендацииподиагностикеикоррекциинарушений липидного обмена с целью профилактики и леченияатеросклероза,четвертыйпересмотр//Российскийкардиологическийжурнал. – 2012. - №4.

- Приложение 1248.https://www.kidney.org/professionals/kdoqi/GFR_calculator249.Рабочая группа по лечению артериальной гипертонии ЕвропейскогоОбщества Гипертонии (European Society of Hypertension, ESH)и Европейского Общества Кардиологов (European Society of Cardiology,ESC 2013250.Herbert A., Cruickshank J., Laurent S., Boutouyrie P. Establishingreference values for central blood pressure and its amplification in a generalhealthy population and according to cardiovascular risk factors. Eur Heart J2014;35(44):3122-33251.Laurent, S.

Expert consensus document on arterial stiffness:methodological issues and clinical applications / S. Laurent, J. Cockroft, LucVan Bortel et al. // EuropeanHeart Journal. – 2006. – № 27. – Р. 2588–2006252.Determinants of pulse wave velocity in healthy people and in thepresence of cardiovascular risk factors: ‗establishing normal and referencevalues в European Heart Journal Advance Access published June 7, 2010253.Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to healthplans of poor glycemic control. Diabetes Care.

Dec; 1997 20(12):1847–53]Gilmer TP, O'Connor PJ, Rush WA, Crain AL, Whitebird RR, Hanson AM, etal. Predictors of health care costs in adults with diabetes. Diabetes Care. Jan;2005 28(1):59–64254.2007 August 24 Complications of Diabetes in the United States.Available from: http://www.diabetes.org/diabetes-statistics/complications.jsp255.Сummings D.M., Doherty L., Howards G.

et al. Blood pressure controlin diabetes: temporal progress yet persistent racial disparities: national resultsfrom the REasons for Geographic And Racial Differences in Stroke(REGARDS) study. Diabetes Care. 2010;33(4):798-803. doi: 10.2337/dc091824.138256.Izzo R., de Simone G., Chinali M. et al. Insufficient control ofblood pressure and incident diabetes. Diabetes Care. 2009;32(5):845-50. doi:10.2337/dc08-1881.257.Choma N., Griffin M., Kaltenbach L. et al. Blood pressure controlamong patients with hypertension and newly diagnosed diabetes.

Diabet Med.2012;29(9):1126-33. doi: 10.1111/j.1464-5491.2011.03548.x.].258./ Augmentation index and arterial stiffness in patients with type 2diabetes mellitus Rachel E.D. Climie, Sonja B. Nikolic, Petr Otahal, Laura J.Keith, James E. Sharman259.Aortic-Brachial Stiffness Mismatch and Mortality in DialysisPopulation Catherine Fortier, Fabrice Mac-Way260.DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areasunder two or more correlated receiver operating characteristic curves: Anonparametric approach.

Biometrics. 1988;44:837-845261.Kobalava Z.D., Villevalde S.V. Azilsartan medoxomil: new horizons inthe treatment of arterial hypertension. Pharmacological properties. Kardiologiia2014;12:57-62 – Russian (Кобалава Ж.Д., Виллевальде С.В.

Азилсартанамедоксомил: новые возможности в лечении артериальной гипертонии.Фармакологические свойства. Кардиология 2014;12:57-62)262.Skibitskiy V.V., Fendrikova A.V., Sirotenko D.V., Skibitskiy A.V.Chronotherapeutic aspects of the efficacy of combination treatment withazilsartan medoxomil in patients with arterial hypertension and metabolicsyndrome. Kardiologiia 2016;10:35-40 – Russian (Скибицкий В.В,Фендрикова А.В., Сиротенко Д.В., Скибицкий А.В.Хронотерапевтические аспекты эффективности азилсартана медоксомилав составе комбинированной терапии у пациентов с артериальнойгипертонией и метаболическим синдромом. Кардиология 2016;10:35-40)263.Ojima M., Igata H., Tanaka M., Sakamoto H., Kuroita T. et al.

In vitroantagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan,in receptor binding and function studies. J Pharmacol Exp Ther2011;336(3):801–8.264.White W.B., Cuadra R.H., Lloyd E., Bacris G.L., Kupfer S. Effects ofazilsartan medoxomil compared with olmesartan and valsartan on ambulatoryand clinic blood pressure in patients with type 2 diabetes and prediabetes. JHypertens 2016;34(4):788-97.265.White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C et al.

Effectsof the angiotensin receptor blocker azilsartan medoxomil on ambulatory andclinic blood pressure in patients with stages 1 and 2 hypertension.Hypertension 2011; 57(3): 413–420139266.Georgiopoulos G., Katsi V., Oikonomou D., Vamvakou G., Koutli E.,Laina A., Tsioufis C., Nihoyannopoulos P., Tousoulis D. Azilsartan as a PotentAntihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: AReview Study.

Front Pharmacol. 2016 Aug 3;7:235267.. Sica D., White W.B., Weber M.A., Bakris G.L., Perez A., Cao C.,Handley A., Kupfer S. Comparison of the novel angiotensin II receptor blockerazilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. JClin Hypertens (Greenwich) 2011;13(7):467–72.140.